Grupo Espanol de Tumores Neuroendocrinos

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 4 drugs with upcoming expirations

Activity

Key Events

Dec 18, 2025TrialRefractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

Jul 30, 2025FDARobaxin — ATMEKSI

Jun 12, 2025TrialRandomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

Sep 13, 2024TrialSacituzumab govitEcan in THYroid Cancers

Oct 27, 2023TrialEfficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

May 25, 2023TrialCabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Jul 27, 2022FDAJatenzo — KYZATREX

Mar 28, 2022FDAJatenzo — TLANDO

4 more events

Oct 7, 2020TrialTrial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study

Oct 11, 2019TrialPlatinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Apr 2, 2019TrialDurvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

Mar 27, 2019FDAJatenzo — JATENZO

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

16 patent groups across drugs · Source: FDA Orange Book

DrugExpires

JatenzoApr 14, 2026 Jatenzo3 patentsJan 6, 2027 OpanaJun 21, 2027 GocovriJan 22, 2028 Jatenzo4 patentsJan 8, 2029 Opana2 patentsJul 10, 2029 Gocovri7 patentsMar 13, 2030 Jatenzo16 patentsApr 12, 2030

8 more

Jatenzo2 patentsMar 15, 2033 Gocovri3 patentsJun 17, 2034 JatenzoNov 28, 2037 Gocovri10 patentsFeb 15, 2038 Jatenzo3 patentsFeb 21, 2039 JatenzoOct 16, 2040 Jatenzo2 patentsMar 29, 2041 RobaxinOct 9, 2044

Regulatory

Regulatory Timeline

19824 events

FDAJan 1

Moban — MOBAN

Application NDA017938 (NDA)

FDAJan 1

Gocovri — SYMMETREL

Application NDA016020 (NDA)

FDAJan 1

Gocovri — SYMMETREL

Application NDA016023 (NDA)

FDAJan 1

Gocovri — SYMMETREL

Application NDA018101 (NDA)

19961 event

FDANov 5

Nascobal — NASCOBAL

Application NDA019722 (NDA)

19981 event

FDASep 25

Valstar Preservative Free — VALSTAR PRESERVATIVE FREE

Application NDA020892 (NDA)

20011 event

FDANov 8

Frova — FROVA

Application NDA021006 (NDA)

20051 event

FDAJan 31

Nascobal — NASCOBAL

Application NDA021642 (NDA)

20062 events

FDAJun 22

Opana — OPANA

Application NDA021611 (NDA)

FDAJun 22

Opana — OPANA ER

Application NDA021610 (NDA)

20071 event

FDAJul 27

Nascobal — CALOMIST

Application NDA022102 (NDA)

20101 event

FDAFeb 2

Xiaflex — XIAFLEX

Application BLA125338 (BLA)

20111 event

FDADec 9

Opana — OPANA ER

Application NDA201655 (NDA)

20141 event

FDAMar 5

Jatenzo — AVEED

Application NDA022219 (NDA)

20171 event

FDAAug 24

Gocovri — GOCOVRI

Application NDA208944 (NDA)

20181 event

FDAFeb 16

Gocovri — OSMOLEX ER

Application NDA209410 (NDA)

20191 event

FDAMar 27

Jatenzo — JATENZO

Application NDA206089 (NDA)

20222 events

FDAJul 27

Jatenzo — KYZATREX

Application NDA213953 (NDA)

FDAMar 28

Jatenzo — TLANDO

Application NDA208088 (NDA)

20251 event

FDAJul 30

Robaxin — ATMEKSI

Application NDA219843 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)